FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2016
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris
.
Date: 1 JUNE 2016
|
Name of applicant:
|
ASTRAZENECA PLC
|
|
Name of scheme:
|
ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
|
|
Period of return:
|
From:
|
1 DECEMBER 2015
|
To:
|
31 MAY 2016
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
4,754,943
|
|
Plus:
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
0
|
|
Less:
Number of
securities
issued/allotted under scheme(s) during period (see LR3.5.7G):
|
689,200
|
|
Equals:
Balance under scheme(s) not yet issued/allotted at end of period:
|
4,065,743
|
|
Name of contact:
|
MARTIN BENNETT
|
|
Telephone number of contact:
|
07825 530066
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 01 June 2016
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|